157 related articles for article (PubMed ID: 33283224)
1. Investigation of the Prognostic Significance of Neuroendocrine Differentiation in Gleason Score 7 to 10 Prostate Adenocarcinoma in Patients With Distant Metastasis After Definitive Radiotherapy.
Mankuzhy NP; Almahariq MF; Ye H; Amin M; Stone B; Krauss DJ
Am J Clin Pathol; 2021 May; 155(6):879-886. PubMed ID: 33283224
[TBL] [Abstract][Full Text] [Related]
2. Chromogranin A staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy.
Krauss DJ; Amin M; Stone B; Ye H; Hayek S; Cotant M; Hafron J; Brabbins DS
Prostate; 2014 May; 74(5):520-7. PubMed ID: 24375481
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy.
Krauss DJ; Hayek S; Amin M; Ye H; Kestin LL; Zadora S; Vicini FA; Cotant M; Brabbins DS; Ghilezan MI; Gustafson GS; Martinez AA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e119-25. PubMed ID: 21596486
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.
Bostwick DG; Qian J; Pacelli A; Zincke H; Blute M; Bergstralh EJ; Slezak JM; Cheng L
J Urol; 2002 Sep; 168(3):1204-11. PubMed ID: 12187268
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
[TBL] [Abstract][Full Text] [Related]
6. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.
Bollito E; Berruti A; Bellina M; Mosca A; Leonardo E; Tarabuzzi R; Cappia S; Ari MM; Tampellini M; Fontana D; Gubetta L; Angeli A; Dogliotti L
Ann Oncol; 2001; 12 Suppl 2():S159-64. PubMed ID: 11762345
[TBL] [Abstract][Full Text] [Related]
7. Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
Tom MC; Nguyen JK; Lucianò R; Mian OY; Stephans KL; Ciezki JP; Smile TD; Wei W; McKenney JK; Magi-Galluzzi C; Tendulkar RD
J Urol; 2019 Oct; 202(4):710-716. PubMed ID: 31059665
[TBL] [Abstract][Full Text] [Related]
8. Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis.
Spratt DE; Zumsteg Z; Ghadjar P; Pangasa M; Pei X; Fine SW; Yamada Y; Kollmeier M; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1254-61. PubMed ID: 23182392
[TBL] [Abstract][Full Text] [Related]
9. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate.
Tamas EF; Epstein JI
Am J Surg Pathol; 2006 Aug; 30(8):980-5. PubMed ID: 16861969
[TBL] [Abstract][Full Text] [Related]
11. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
Sciarra A; Di Silverio F; Autran AM; Salciccia S; Gentilucci A; Alfarone A; Gentile V
Urol Int; 2009; 82(2):147-51. PubMed ID: 19321999
[TBL] [Abstract][Full Text] [Related]
12. Long-term Results of External Beam Radiotherapy for Prostate Cancer with Prostate-specific Antigen of More Than 50 ng/ml and Without Evidence of Lymph Node or Distant Metastasis.
Umezawa R; Inaba K; Nakamura S; Wakita A; Okamoto H; Shima S; Tsuchida K; Kashihara T; Kobayashi K; Harada K; Takahashi K; Murakami N; Ito Y; Igaki H; Jingu K; Itami J
Anticancer Res; 2018 Apr; 38(4):2303-2309. PubMed ID: 29599353
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of focal neuroendocrine differentiation in prostate cancer: cases with autopsy-verified cause of death.
Tarján M
Indian J Urol; 2010; 26(1):41-5. PubMed ID: 20535283
[TBL] [Abstract][Full Text] [Related]
15. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
16. Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2004 Dec; 4(1):14. PubMed ID: 15588310
[TBL] [Abstract][Full Text] [Related]
17. Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize?
Montironi R; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Santoni M; Briganti A; Montorsi F; Cheng L
Diagn Pathol; 2014 Oct; 9():190. PubMed ID: 25326076
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
20. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]